Longer-term analyses reinforce duvelisib’s activity across treatment-experienced PTCL populations, including patients with ≥3 prior lines of therapy, with no new safety signals emerging over time.

I spoke with experts to discover how, when and why wellness influencers have gained the ability to spread health misinformation on social media.

Unlike lighting, which can be replaced by candles in an emergency, refrigeration has no easy substitute. When the power goes ...

More people are recognizing ADHD symptoms today. This surge in awareness stems from better understanding, social media ...

Selective Treg modulator gotistobart (BNT316/ONC-392) showed a reduction in the risk of death by more than half compared to standard of care ...

Blood tests for Alzheimer’s disease are rapidly moving into clinics, promising earlier and easier detection of brain changes ...

Follow-up data from CARTITUDE-4 show at least 80 percent of as-treated standard-risk patients remained progression- and treatment-free following a single infusion as early as second line1 ...

EPCORE® DLBCL-3 Trial Results Separately, new results from the ongoing Phase 2 EPCORE DLBCL-3 trial (abstract 63), for fixed-duration epcoritamab monotherapy in newly diagnosed elderly patients with ...